{"title":"PCSK9 抑制剂在实际临床实践中的疗效和耐受性。","authors":"Prashasthi Devaiah, Sava Handjiev, Jacob George","doi":"10.5837/bjc.2023.044","DOIUrl":null,"url":null,"abstract":"<p><p>Despite widespread use of statins and other lipid-lowering therapies for hypercholesterolaemia, cardiovascular (CV) mortality and morbidity remains high. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved for use in patients with familial hypercholesterolaemia and high CV risk in the UK. We reviewed the records of patients at a large health board in Scotland, who were prescribed these agents, to determine their real- world efficacy and tolerability in routine clinical care.</p>","PeriodicalId":74959,"journal":{"name":"The British journal of cardiology","volume":"30 4","pages":"44"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376256/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and tolerability of PCSK9 inhibitors in real-world clinical practice.\",\"authors\":\"Prashasthi Devaiah, Sava Handjiev, Jacob George\",\"doi\":\"10.5837/bjc.2023.044\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Despite widespread use of statins and other lipid-lowering therapies for hypercholesterolaemia, cardiovascular (CV) mortality and morbidity remains high. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved for use in patients with familial hypercholesterolaemia and high CV risk in the UK. We reviewed the records of patients at a large health board in Scotland, who were prescribed these agents, to determine their real- world efficacy and tolerability in routine clinical care.</p>\",\"PeriodicalId\":74959,\"journal\":{\"name\":\"The British journal of cardiology\",\"volume\":\"30 4\",\"pages\":\"44\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376256/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The British journal of cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5837/bjc.2023.044\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The British journal of cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5837/bjc.2023.044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Efficacy and tolerability of PCSK9 inhibitors in real-world clinical practice.
Despite widespread use of statins and other lipid-lowering therapies for hypercholesterolaemia, cardiovascular (CV) mortality and morbidity remains high. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved for use in patients with familial hypercholesterolaemia and high CV risk in the UK. We reviewed the records of patients at a large health board in Scotland, who were prescribed these agents, to determine their real- world efficacy and tolerability in routine clinical care.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
